CLINICAL RESULTS WITH A PREMIUM MONOFOCAL IOL IN TWO EUROPEAN CLINICS
Sponsored by
In both settings, patient satisfaction was high with the ISOPURE IOL. Beaver-Visitec International
BY RAFAEL BILBAO-CALABUIG, MD, PHD, FEBOS-CR, AND KRISTOF VANDEKERCKHOVE, MD
A LOW RISK FOR VISUAL DISTURBANCES
RAFAEL BILBAO-CALABUIG, MD, PHD, FEBOS-CR
Trifocal diffractive IOLs are monofocal IOL (data on file with Results. Mean distance visual acuity was
currently the gold standard for lenticular Beaver-Visitec International). Additionally, 0.95, and mean intermediate vision was
presbyopia surgical correction. These lenses, on the optical bench, contrast sensitivity 0.66 monocularly and 0.75 binocularly.
however, have some undesirable visual side with the lens is comparable to that of a We obtained a widened defocus curve
effects for certain patients. In my opinion, standard monofocal IOL. with a binocular visual acuity superior
extended depth of focus (EDOF) IOLs are an The ISOPURE provides a greater depth of to 0.2 logMAR from 62 cm to distance.
exciting alternative to trifocal technologies. focus compared to a standard monofocal Contrast sensitivity curves were within the
One lens, the ISOPURE (Beaver-Visitec IOL at different pupil sizes, offering a con- normal values for the age group.
International), is especially promising. tinuous increase in quality of vision between Patient satisfaction was high in the
The ISOPURE is designed to provide func- distance and intermediate. binocular group, with 90% of patients
tional intermediate vision in all conditions stating they did not experience halos or
without compromising quality of vision. It is CLINICAL STUDY glare. For the other 10%, the halos or glare
a nondiffractive aspheric IOL with a patent- Study design. We performed a were not bothersome. Additionally, 90%
ed polynomial surface design across the full prospective clinical study to evaluate the of patients didn't need glasses for distance
optic that accentuates the extended depth clinical results after cataract surgery with or intermediate vision and 50% said they
of focus effect without inducing photic phe- ISOPURE implantation. Patients were fol- achieved uncorrected functional near vision
nomena such as halos, glare, and starbursts. lowed for 6 months. The target refraction for short durations and easy visual tasks.
Optical bench testing has shown that was 0.00 D when implanted monocularly With these initial promising results,
the ISOPURE provides about 50% greater and -0.50 to -0.75 D in the implanted eye our group has now implanted more than
depth of focus than a standard aspheric when implanted binocularly. 400 ISOPURE lenses across Spain.
EXCELLENT INTERMEDIATE VISUAL ACUITY
KRISTOF VANDEKERCKHOVE, MD
Prior to introducing the (≤ -0.1 logMAR) and an
ISOPURE IOL in our clinic extended range of uncorrected
in March 2020, about 90% of implanted vision. The defocus curve
IOLs were monofocal. Within 8 months, showed a smooth slope over
ISOPURE reached 30% of the IOL share the tested diopter range,
in our practice. After 18 months, I had resulting in a functional depth
implanted more than 800 ISOPURE lenses. of focus (≤ 0.2 logMAR) of
The key factors for this rapid adoption 2.40 D (Figure). Spectacle
were our extensive and positive experience independence was 93% at Figure. The mean functional elongation of depth of focus.
with the same IOL platform (Micropure, intermediate and 40% at
Beaver-Visitec International) and the clear near. Quality of vision was
positioning of ISOPURE by our team. uncompromised, with halos reported RAFAEL BILBAO-CALABUIG, MD, PHD, FEBOS-CR
n C línica Baviera/AIER Group, Madrid, Spain
Early data and experience from our own by only 7%, starburst by 14%, and
n r
[email protected]retrospective trial reinforced internal glare by 18% of patients 4 to 6 weeks
n F inancial disclosure: Scientific Consultant
confidence. after surgery.
We conducted a retrospective clinical These results encouraged us to (Beaver-Visitec International/PhysIOL)
trial in 50 cataract patients (100 eyes) after initiate a prospective head-to-head KRISTOF VANDEKERCKHOVE, MD
bilateral implantation of the ISOPURE. study between ISOPURE and another n H ead and founder, Vista Alpina Eye Clinic, Switzerland
Patients achieved uncompromised next-generation EDOF IOL (AcrySof IQ n v
[email protected]uncorrected distance visual acuity Vivity, Alcon). n n F inancial disclosure: None
MARCH 2022 | INSERT TO CATARACT & REFRACTIVE SURGERY TODAY EUROPE 23
